Incidence and risk factors for new-onset diabetes in living-donor liver transplant recipients

Clinical Transplantation

Volumn 27, Issue 3, 2013, Pages 426-435

  Honda, Masaki ^a   Asonuma, Katsuhiro ^a   Hayashida, Shintaro ^a   Suda, Hiroko ^a   Ohya, Yuki ^a   Lee, Kwang Jong ^a   Yamamoto, Hidekazu ^a   Takeichi, Takayuki ^a   Inomata, Yukihiro ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Diabetes mellitus; Immunosuppression; Liver to spleen ratio; Living donor liver transplantation; New onset diabetes after transplantation

Indexed keywords

CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG PULSE THERAPY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HAZARD RATIO; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LIVER TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEW ONSET DIABETES AFTER TRANSPLANTATION; PRACTICE GUIDELINE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; WORLD HEALTH ORGANIZATION; ADOLESCENT; CLINICAL TRIAL; COHORT ANALYSIS; COMPLICATION; DIABETES COMPLICATIONS; GRAFT REJECTION; JAPAN; LIVER DISEASES; MIDDLE AGED; PROGNOSIS; SURVIVOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; JAPAN; LIVER DISEASES; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SURVIVORS; YOUNG ADULT;

EID: 84878641529     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12103     Document Type: Article

References (42)

1. Kuo HT, Sampaio MS, Ye X, Reddy P, Martin P, Bunnapradist S. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing database. Transplantation 2010: 89: 1134.
2. Saab S, Shpaner A, Zhao Y et al. Prevalence and risk factors for diabetes mellitus in moderate term survivors of liver transplantation. Am J Transplant 2006: 6: 1890.
3. Van Laecke S, Desideri F, Geerts A et al. Hypomagnesemia and the risk of new-onset diabetes after liver transplantation. Liver Transpl 2010: 16: 1278.
4. Davidson J, Wilkinson A, Dantal J et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003: 75(10 Suppl): SS3.
5. Benhamou PY, Penfornis A. Natural history, prognosis, and management of transplantation-induced diabetes mellitus. Diabete Metab 2002: 28: 166.
6. Bostom AD, Brown RS Jr, Chavers BM et al. Prevention of post-transplant cardiovascular disease-report and recommendations of an ad hoc group. Am J Transplant 2002: 2: 491.
7. Baid S, Cosimi AB, Farrell ML et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001: 72: 1066.
8. Moon JI, Barbeito R, Faradji RN, Gaynor JJ, Tzakis AG. Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: long-term follow up. Transplantation 2006: 82: 1625.
9. Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004: 4: 583.
10. Khalili M, Lim JW, Bass N, Ascher NL, Roberts JP, Terrault NA. New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl 2004: 10: 349.
11. Vincenti F, Friman S, Scheuermann E et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007: 7: 1506.
12. Saliba F, Lakehal M, Pageaux GP et al. Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection: an observational multicenter study. Liver Transpl 2007: 13: 136.
13. Oufroukhi L, Kamar N, Muscari F et al. Predictive factors for posttransplant diabetes mellitus within one-year of liver transplantation. Transplantation 2008: 85: 1436.
14. Chen T, Jia H, Li J, Chen X, Zhou H, Tian H. New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies. Transpl Int 2009: 22: 408.
15. Bayer ND, Cochetti PT, Anil Kumar MS et al. Association of metabolic syndrome with development of new-onset diabetes after transplantation. Transplantation 2010: 90: 861.
16. Kishi Y, Sugawara Y, Tamura S, Kaneko J, Matsui Y, Makuuchi M. New-onset diabetes mellitus after living donor liver transplantation: possible association with hepatitis C. Transplant Proc 2006: 38: 2989.
17. Zhao J, Yan L, Li B et al. Diabetes mellitus after living donor liver transplantation: data from mainland China. Transplant Proc 2009: 41: 1756.
18. Brunt EM, Janney CG, DiBisceglie AM, Neuschwander-Terri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999: 94: 2467.
19. Iwasaki M, Takada Y, Hayashi M et al. Noninvasive evaluation of graft steatosis in living donor liver transplantation. Transplantation 2004: 78: 1501.
20. Jain A, Venkataramanan R, Sharma R et al. Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipients. Transplantation 2008: 85: 554.
21. Yang J, Hutchinson II, Shah T, Min DI. Genetic and clinical risk factors of new-onset diabetes after transplantation in Hispanic kidney transplant recipients. Transplantation 2011: 91: 1114.
22. Kuo HT, Poommipanit N, Sampaio M, Reddy P, Cho YW, Bunnapradist S. Risk factors for development of new-onset diabetes mellitus in pediatric renal transplant recipients: an analysis of the OPTN/UNOS database. Transplantation 2010: 89: 434.
23. Nakamuta M, Morizono S, Soejima Y et al. Short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation. Transplantation 2005: 80: 608.
24. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 2010: 375: 2267.
25. Samuel VT, Liu ZX, Qu X et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004: 279: 32345.
26. Marsman WA, Wiesner RH, Rodriguez L et al. Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation 1996: 62: 1246.
27. McCormack L, Petrowsky H, Jochum W, Mullhaupt B, Weber M, Clavien PA. Use of severely steatotic grafts in liver transplantation: a matched case-control study. Ann Surg 2007: 246: 940.
28. McCormack L, Dutkowski P, El-Badry AM, Clavien PA. Liver transplantation using fatty livers: always feasible? J Hepatol 2011: 54: 1055.
29. Kamada Y, Takehara T, Hayashi N. Adipocytokines and liver disease. J Gastroenterol 2008: 43: 811.
30. Levy G, Villamil F, Samuel D et al. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004: 77: 1632.
31. Marchetti P. New-onset diabetes after liver transplantation: from pathogenesis to management. Liver Transpl 2005: 11: 612.
32. Johnson JD, Ao Z, Ao P et al. Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets. Cell Transplant 2009: 18: 833.
33. Tamura S, Sugawara Y, Kishi Y et al. Conversion to cyclosporine provides valuable rescue therapy for living donor adult liver transplant patients intolerant to tacrolimus: a single-center experience at the University of Tokyo. Transplant Proc 2004: 36: 3242.
34. Dumortier J, Bernard S, Bouffard Y, Boillot O. Conversion from tacrolimus to cyclosporine in liver transplanted patients with diabetes mellitus. Liver Transpl 2006: 12: 659.
35. Ghisdal L, Bouchta NB, Broeders N et al. Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature. Transpl Int 2008: 21: 146.
36. Chan JC, Cockram CS, Critchley JA. Drug-induced disorders of glucose metabolism. Mechanisms and management. Drug Saf 1996: 15: 135.
37. Starzl TE, Murase N, Abu-Elmagd K et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003: 361: 1502.
38. Alexander JW, Metze TJ, McIntosh MJ et al. The influence of immunomodulatory diets on transplant success and complications. Transplantation 2005: 79: 460.
39. Alexander JW, Goodman HR, Cardi M et al. Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation. Transpl Int 2006: 19: 295.
40. Alsatie M, Pandya P, Chalasani NP. Insulin resistance, hepatitis C, and liver transplantation. Liver Transpl 2008: 14: 136.
41. Delgado-Borrego A, Liu YS, Jordan SH et al. Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance. Liver Transpl 2008: 14: 193.
42. Baid-Agrawal S, Frei U, Reinke P et al. Impaired insulin sensitivity as an underlying mechanism linking hepatitis C and posttransplant diabetes mellitus in kidney recipients. Am J Transplant 2009: 9: 2777.